ArticleJCO precision oncology2019
Genomic Characterization of
Article in JCO precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 38 citations in OpenAlex.
- Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Molecular convergence in gallbladder cancer: MEK-ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks.Cancer cell international · 2026Review
- Challenges and innovations in adjuvant therapy for gallbladder cancer: a meta-analytic perspective.Hepatobiliary surgery and nutrition · 2026Article
- Targeting Biliary Tract Cancers with Antibody-Drug Conjugates: Advances in Molecular Targets and Rational Combinations.Cancers · 2026Review
- Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.Journal of gastroenterology · 2026Article
- Response of HER2 positive gallbladder adenocarcinoma to trastuzumab emtansine (T-DM1): a case report and literature review.Frontiers in oncology · 2026Article
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy forJCO precision oncology · 2025Article
- Epidemiology and genomic features of biliary tract cancer and its unique features in Korea.Journal of liver cancer · 2025Article
- Clinical and Genomic Characterization ofJCO global oncology · 2024Article
- Review
- Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.Molecular cancer · 2024Review
- Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.Diagnostics (Basel, Switzerland) · 2023Article
- Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives.Cancers · 2023Review
- Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials.JCO precision oncology · 2023Review
- Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.Cancers · 2023Review
- At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.Nature reviews. Clinical oncology · 2023Review
- Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.Nature communications · 2023Article
- Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers.Frontiers in molecular biosciences · 2023Review
- Rational development of combination therapies for biliary tract cancers.Journal of hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
purposeBiliary tract cancers (BTCs), which include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC), and gallbladder cancer (GBC), have limited treatment options. We sought to comprehensively examine the clinical and molecular characteristics of BTCs with amplification or mutation of
methodsDemographic, outcome, and treatment response data were collected for patients with
resultsA total of 517 patients with BTC underwent next-generation sequencing (ICC, n = 313; EHC, n = 93; GBC, n = 111). Twenty-eight patients (5.4%) had
conclusion
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.